Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy | Zendy

Sajoscha Sorrentino | Zendy; Christian Besler | Zendy; Lucia Rohrer | Zendy; Martin Meyer | Zendy; Kathrin Heinrich | Zendy; Ferdinand H. Bahlmann | Zendy; Maja Mueller | Zendy; Tibor Horváth | Zendy; Carola Doerries | Zendy; Mariko Heinemann | Zendy; Stella Flemmer | Zendy; Andrea Markowski | Zendy; Costantina Manes | Zendy; Mathias Bähr | Zendy; Hermann Haller | Zendy; Arnold von Eckardstein | Zendy; Helmut Drexler | Zendy; Ulf Landmesser | Zendy

Open Access

Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy

Author(s) -

Sajoscha Sorrentino,

Christian Besler,

Lucia Rohrer,

Martin Meyer,

Kathrin Heinrich,

Ferdinand H. Bahlmann,

Maja Mueller,

Tibor Horváth,

Carola Doerries,

Mariko Heinemann,

Stella Flemmer,

Andrea Markowski,

Costantina Manes,

Mathias Bähr,

Hermann Haller,

Arnold von Eckardstein,

Helmut Drexler,

Ulf Landmesser

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.836346

Subject(s) - niacin , medicine , endothelial dysfunction , endocrinology , endothelium , vasoprotective , endothelial stem cell , nitric oxide , progenitor cell , diabetes mellitus , endothelial progenitor cell , lipoprotein , type 2 diabetes , high density lipoprotein , cholesterol , biochemistry , chemistry , biology , stem cell , microbiology and biotechnology , in vitro

High-density lipoprotein (HDL)-raising therapies are currently under intense evaluation, but the effects of HDL may be highly heterogeneous. We therefore compared the endothelial effects of HDL from healthy subjects and from patients with type 2 diabetes mellitus and low HDL (meeting the criteria for metabolic syndrome), who are frequently considered for HDL-raising therapies. Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research